Cosentyx (secukinumab) is a biologic medication used to treat certain autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. According to the product information provided by the European Medicines Agency (EMA), dosage adjustments are not necessary for patients with mild to moderate renal impairment or mild hepatic impairment [3]. However, patients with moderate to severe hepatic impairment should be closely monitored, and a dose adjustment may be necessary [3].

The recommended dosage of Cosentyx is 300 mg subcutaneously once a week for the first 5 weeks, followed by 300 mg every 4 weeks thereafter [3]. The drug is administered via injection and should be given by a healthcare professional or a patient who has been properly trained [2].

It is important to note that the information provided in the sources is intended as a general guideline, and individual patient factors may necessitate a dosage adjustment. Patients should always consult with their healthcare provider regarding any questions or concerns about their medication regimen [1].

In conclusion, according to the sources provided, a dosage adjustment may be necessary for patients with moderate to severe hepatic impairment, but is generally not required for patients with mild to moderate renal impairment or mild hepatic impairment. The recommended dosage of Cosentyx is 300 mg subcutaneously once a week for the first 5 weeks, followed by 300 mg every 4 weeks thereafter. However, individual patient factors may necessitate a dosage adjustment, and patients should always consult with their healthcare provider regarding any questions or concerns about their medication regimen.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[3] https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf